Pulmonary Dendritic Cells

Cook, Donald N.; Nakano, Hideki

doi:10.1016/b978-0-12-404577-4.00033-3

Cited by 2 publications

(1 citation statement)

References 120 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os macrófagos alveolares removem a maioria das partículas nocivas que chegam ao alvéolo e controlam negativamente o quadro inflamatório. Já os macrófagos intersticiais que estão localizados dentro do tecido pulmonar, não estão em contato direto com o fluido alveolar e sua função ainda não está totalmente esclarecida mas acredita-se que auxiliam no controle do quadro inflamatório (COOK; NAKANO, 2015;BELL, 2014;MINUTTI et al, 2017a, b;WRIGHT, 2005). Esses achados mostram a complexidade do sistema imunológico nos diferentes tecidos, e também o papel que a melatonina apresenta na regulação desse sistema de maneira particular para cada tecido, em especial no pulmão, tema deste trabalho (ACUÑA-CASTROVIEJO et al, 2014;STANFORD, 2018).…”

Section: Melatonina Em Pulmão De Ratosunclassified

Pulmão como uma fonte extrapineal de melatonina

Paz¹

View full text Add to dashboard Cite

Section: Melatonina Em Pulmão De Ratosunclassified

Pulmão como uma fonte extrapineal de melatonina

Paz¹

View full text Add to dashboard Cite

Advances in the Lung Cancer Immunotherapy Approaches

et al. 2022

View full text Add to dashboard Cite

Despite the progress in the comprehension of LC progression, risk, immunologic control, and treatment choices, it is still the primary cause of cancer-related death. LC cells possess a very low and heterogeneous antigenicity, which allows them to passively evade the anticancer defense of the immune system by educating cytotoxic lymphocytes (CTLs), tumor-infiltrating lymphocytes (TILs), regulatory T cells (Treg), immune checkpoint inhibitors (ICIs), and myeloid-derived suppressor cells (MDSCs). Though ICIs are an important candidate in first-line therapy, consolidation therapy, adjuvant therapy, and other combination therapies involving traditional therapies, the need for new predictive immunotherapy biomarkers remains. Furthermore, ICI-induced resistance after an initial response makes it vital to seek and exploit new targets to benefit greatly from immunotherapy. As ICIs, tumor mutation burden (TMB), and microsatellite instability (MSI) are not ideal LC predictive markers, a multi-parameter analysis of the immune system considering tumor, stroma, and beyond can be the future-oriented predictive marker. The optimal patient selection with a proper adjuvant agent in immunotherapy approaches needs to be still revised. Here, we summarize advances in LC immunotherapy approaches with their clinical and preclinical trials considering cancer models and vaccines and the potential of employing immunology to predict immunotherapy effectiveness in cancer patients and address the viewpoints on future directions. We conclude that the field of lung cancer therapeutics can benefit from the use of combination strategies but with comprehension of their limitations and improvements.

show abstract

Pulmonary Dendritic Cells

Cited by 2 publications

References 120 publications

Pulmão como uma fonte extrapineal de melatonina

Pulmão como uma fonte extrapineal de melatonina

Advances in the Lung Cancer Immunotherapy Approaches

Contact Info

Product

Resources

About